Protocol Status: PUBLISHED
Protocol:
Version: 2026.01
Effective Date:
Last Reviewed:
Medical Director Approval:
Clinical Note: This content reflects current GCEMS clinical guidelines as of the dates listed above. If content appears inconsistent with current policy, use the most recent approved guideline and notify leadership for correction.

Racemic Epinephrine

(MicroNEFRIN, Vaponephrine)

 

GCEMS Protocol:

 

  • Pediatric Reactive Airway Disease

 

INDICATIONS:

 

  • Croup (Laryngotracheobronchitis)

 

 

DOSAGE:

ADULT:

 

  • Not indicated for adult patients

 

PEDIATRIC:

 

  • 0.5 ml (diluted to 3.0 ml with NS) nebulized; may not repeat
  • Physician in the receiving ED should be notified that treatment has been administered

 

CONTRAINDICATIONS:

 

  • Should not be used in the management of epiglottitis

 

SIDE EFFECTS:

 

  • Can result in tachycardia and possible arrhythmias